You just read:

Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications

News provided by

Regen BioPharma Inc. and Entest BioMedical's

Oct 19, 2016, 08:00 ET